Last Close
Feb 04  •  04:00PM ET
26.78
Dollar change
+1.01
Percentage change
3.92
%
Feb 03, 12:32 PMPfizer shares fall as quarterly results show a $1.6B loss on $4.4B impairments despite reporting Q4 EPS of $0.66 and FY2025 EPS of $3.22 on $62.6B revenue; it reaffirmed 2026 guidance ($59.5-$62.5B revenue, $2.80-$3.00 EPS), flagged elevated R&D with no 2026 buybacks, and posted positive Phase 2b VESPER-3 data for ultra-long-acting GLP-1 PF-3944 supporting monthly dosing with Phase 3 planned in 2026.
IndexS&P 500 P/E19.76 EPS (ttm)1.36 Insider Own0.09% Shs Outstand5.69B Perf Week3.56%
Market Cap152.26B Forward P/E9.41 EPS next Y2.85 Insider Trans0.00% Shs Float5.68B Perf Month6.40%
Enterprise Value199.29B PEG- EPS next Q0.73 Inst Own66.75% Short Float2.29% Perf Quarter8.60%
Income7.75B P/S2.43 EPS this Y-7.47% Inst Trans-0.36% Short Ratio2.12 Perf Half Y8.20%
Sales62.58B P/B1.64 EPS next Y-4.45% ROA4.58% Short Interest129.80M Perf YTD7.55%
Book/sh16.32 P/C10.16 EPS next 5Y-8.79% ROE10.59% 52W High27.69 -3.29% Perf Year2.21%
Cash/sh2.64 P/FCF14.67 EPS past 3/5Y-37.12% -3.51% ROIC5.16% 52W Low20.92 28.04% Perf 3Y-38.51%
Dividend Est.1.76 (6.56%) EV/EBITDA7.62 Sales past 3/5Y-14.56% 8.48% Gross Margin76.10% Volatility2.50% 2.20% Perf 5Y-25.32%
Dividend TTM1.72 (6.42%) EV/Sales3.18 EPS Y/Y TTM-3.74% Oper. Margin27.83% ATR (14)0.63 Perf 10Y-7.41%
Dividend Ex-DateJan 23, 2026 Quick Ratio0.97 Sales Y/Y TTM-1.65% Profit Margin12.38% RSI (14)59.68 Recom2.39
Dividend Gr. 3/5Y2.23% 2.37% Current Ratio1.28 EPS Q/Q-509.90% SMA203.65% Beta0.44 Target Price28.69
Payout126.47% Debt/Eq0.66 Sales Q/Q-1.16% SMA504.73% Rel Volume1.34 Prev Close25.77
Employees81000 LT Debt/Eq0.62 EarningsFeb 03 BMO SMA2008.50% Avg Volume61.17M Price26.78
IPOJan 17, 1944 Option/ShortYes / Yes EPS/Sales Surpr.16.42% 4.20% Trades Volume82,102,493 Change3.92%
Date Action Analyst Rating Change Price Target Change
Jan-07-26Resumed UBS Neutral $25
Dec-02-25Resumed Citigroup Neutral $26
Nov-13-25Initiated Scotiabank Sector Outperform $30
Apr-22-25Initiated Cantor Fitzgerald Neutral $24
Dec-10-24Resumed BofA Securities Neutral $29
Nov-15-24Initiated Wolfe Research Underperform $25
Oct-25-24Resumed Citigroup Neutral $30
Oct-17-24Initiated Bernstein Mkt Perform $32
Aug-07-24Upgrade Daiwa Securities Neutral → Outperform
Mar-22-24Downgrade Argus Buy → Hold
Today 01:11PM
11:40AM
08:45AM
04:51AM
01:08AM
12:32AM Loading…
12:32AM
Feb-03-26 11:35PM
11:09PM
09:49PM
06:03PM
04:36PM
04:26PM
04:06PM
04:03PM
03:14PM
03:05PM Loading…
03:05PM
02:57PM
02:48PM
02:24PM
02:06PM
01:59PM
12:33PM
12:33PM
12:22PM
11:40AM
11:36AM
11:32AM
11:30AM
11:04AM
11:00AM
10:48AM Loading…
10:48AM
10:40AM
10:35AM
10:32AM
10:26AM
09:59AM
09:36AM
09:36AM
09:30AM
09:02AM
08:50AM
08:45AM
08:19AM
08:19AM
07:55AM
07:38AM
07:28AM
07:24AM
07:21AM
07:19AM
07:02AM
06:53AM
06:45AM
06:40AM
05:25AM
05:12AM
05:00AM
04:19AM
03:01AM
Feb-02-26 07:00PM
06:02PM
02:08PM
01:59PM
11:12AM
10:35AM
10:25AM
08:29AM
08:10AM
07:00AM
06:52AM
06:31AM
06:07AM
02:13AM
Feb-01-26 10:03PM
07:47AM
06:20AM
Jan-31-26 08:28PM
07:49AM
Jan-30-26 04:57PM
01:22PM
11:28AM
10:19AM
09:00AM
08:49AM
08:39AM
07:58AM
07:50AM
07:20AM
07:17AM
05:31AM
Jan-29-26 07:26PM
01:00PM
09:15AM
07:23AM
02:07AM
Jan-28-26 07:23PM
10:49AM
09:48AM
07:48AM
05:51AM
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dolsten MikaelFormer OfficerMay 23 '25Proposed Sale23.0959,7811,380,632May 23 10:54 AM
Dolsten MikaelFormer OfficerMay 05 '25Proposed Sale23.8755,0001,312,736May 05 04:45 PM
DAMICO JENNIFER B.SVP & ControllerMar 04 '25Sale25.932,50064,82511,850Mar 06 01:57 PM
DAMICO JENNIFER B.SVP & ControllerFeb 27 '25Option Exercise31.3122,416701,84531,063Mar 03 05:39 PM
SUSMAN SALLYExecutive Vice PresidentFeb 27 '25Option Exercise31.3185,1822,667,048250,866Mar 03 05:38 PM
SAHNI PAYALExecutive Vice PresidentFeb 27 '25Option Exercise31.3119,054596,58144,242Mar 03 05:38 PM
McDermott MichaelExecutive Vice PresidentFeb 27 '25Option Exercise31.3148,4191,515,999122,413Mar 03 05:37 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 27 '25Option Exercise31.31156,9144,912,977309,790Mar 03 05:37 PM
Fonseca LidiaExecutive Vice PresidentFeb 27 '25Option Exercise31.3172,6292,274,014111,534Mar 03 05:36 PM
BOURLA ALBERTChairman & CEOFeb 27 '25Option Exercise31.31582,82318,248,188931,744Mar 03 05:36 PM
McDermott MichaelExecutive Vice PresidentFeb 22 '25Option Exercise30.1711,125335,64187,636Feb 25 07:38 PM
DAMICO JENNIFER B.SVP & ControllerFeb 22 '25Option Exercise30.178,741263,71617,602Feb 25 07:38 PM
BOURLA ALBERTChairman & CEOFeb 22 '25Option Exercise30.17238,3997,192,498570,436Feb 25 07:06 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 22 '25Option Exercise30.1785,8242,589,310232,775Feb 25 07:05 PM
SAHNI PAYALExecutive Vice PresidentFeb 22 '25Option Exercise30.1712,714383,58137,099Feb 25 07:04 PM
SUSMAN SALLYExecutive Vice PresidentFeb 22 '25Option Exercise30.1763,5731,917,997225,184Feb 25 07:02 PM
BOSHOFF CHRISTOFFELPresident, R&DFeb 22 '25Option Exercise30.178,741263,716159,085Feb 25 06:58 PM
BLAYLOCK RONALD EDirectorFeb 13 '25Buy25.6519,457499,07227,707Feb 14 05:16 PM